Loading company
Aditxt, Inc.
ADTX · OTC
$0.010.0%Sep 25 close
- 1M
- 0.0%
- 6M
- -100.0%
- 1Y
- -100.0%
- 5Y
- -100.0%
ADTX · OTC
$0.010.0%Sep 25 close
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $12.2K | $1K | +1,094.40% |
| Profit | -$15.9M | -$5.7M | -179.28% |
| Profit per share | -$3.45 | -$0.37 | -832.43% |
| Free Cash Flow | -$4.6M | -$4M | -15.98% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Aditxt, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Therapeutics Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Aditxt, Inc.’s Item 2.02 8-K filed November 13, 2020; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.